Record mula sa primary source
Decision-gradeIba pa
Halozyme Therapeutics para Bilhin ang Elektrofi sa $750M Upfront
Ang Halozyme Therapeutics ay pumasok sa isang Kasunduan at Plano ng Pagsasama upang bilhin ang Elektrofi para sa paunang bayad na $750 milyon sa cash, kasama ang hanggang tatlong $50 milyon na bayad sa milestone na nakasalalay sa mga pag-apruba ng regulasyon ng produkto. Ang pagkuha ay napapailalim sa mga karaniwang kondisyon sa pagsasara, kasama ang pagsusuri ng antitrust.
Mahahalagang fact
- Na-file
- Okt 3, 2025, 08:51 PM
- Kaganapan
- Iba pa
- Direksyon
- Neutral
- Kumpanya
HALOHalozyme- Pinagmulan
- SEC 8-K
- Kumpiyansa
- May source
Sipi mula sa source
8-K false 0001159036 0001159036 2025-09-30 2025-09-30 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): September 30, 2025 HALOZYME THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Commission File Number 001-32335 Delaware 88-0488686 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) 12390 El Camino Real San Diego California 92130 (Address of principal executive offices) (Zip Code) (858) 794-8889 (Registrant’s telephone number, including area code) Not Applicable (Former name or former address, if changed since last report) Check the ap